Measurement of Glucose Metabolism in Humans: Effect of Recurrent Hypoglycemia on Hypothalamic GABA (GABA)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02829593 |
Recruitment Status :
Recruiting
First Posted : July 12, 2016
Last Update Posted : February 14, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Type 1 Diabetes Healthy | Other: hypoglycemia (low blood sugar) and MRI | Not Applicable |
Glucose is a major fuel for most organs in the human body, particularly the brain. How and where the body uses glucose is regulated by a number of hormones, for instance insulin and glucagon. In a number of diseases, in particular diabetes mellitus, the glucose supply to the brain may be different than normal, which may be a cause for reduced glucose awareness.
The purpose of this study is to determine the effects of altered glucose metabolism on the brain. For example, patients with long duration diabetes mellitus lose their ability to secrete the hormones necessary to protect them against hypoglycemia, which may be due to alterations in glucose availability to the human brain.
To measure these effects, we will use intravenous infusions of glucose and insulin.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 40 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Supportive Care |
Official Title: | Measurement of Glucose Metabolism in Humans Using Magnetic Resonance at 7 Tesla: Effect of Recurrent Hypoglycemia on Hypothalamic GABA |
Actual Study Start Date : | October 31, 2019 |
Estimated Primary Completion Date : | May 31, 2023 |
Estimated Study Completion Date : | May 31, 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: type 1 diabetes
type 1 diabetes >5 years duration
|
Other: hypoglycemia (low blood sugar) and MRI
hypoglycemia (low blood sugar) and MRI |
Placebo Comparator: healthy controls |
Other: hypoglycemia (low blood sugar) and MRI
hypoglycemia (low blood sugar) and MRI |
- Change in Euglycemic GABA level in hypothalamus using MRI [ Time Frame: Baseline to 2 month ]MRI measurement of GABA in the hypothalamus

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- well controlled type 1 diabetes (hemoglobin A1c <7.5%)
- age 18-65
- healthy controls
Exclusion Criteria:
- history of stroke, seizures, neurosurgical procedures, or arrhythmias
- use of drugs that can alter GABA metabolism (such as benzodiazepines).
- Subjects must also meet requirements for a study in the magnet, which includes weight less than 300 lbs and the absence of metallic substances in their body.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02829593
Contact: Anjali Kumar, PA-C | 612-301-7040 | studydiabetes@umn.edu | |
Contact: Elizabeth Seaquist, MD | 612-624-9176 |
United States, Minnesota | |
University of Minnesota | Recruiting |
Minneapolis, Minnesota, United States, 55455 | |
Contact: Anjali Kumar, PA-C 612-301-7040 studydiabetes@umn.edu | |
Principal Investigator: Elizabeth Seaquist, MD |
Responsible Party: | University of Minnesota |
ClinicalTrials.gov Identifier: | NCT02829593 |
Other Study ID Numbers: |
1511M80568 |
First Posted: | July 12, 2016 Key Record Dates |
Last Update Posted: | February 14, 2023 |
Last Verified: | February 2023 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Hypoglycemia Glucose Metabolism Disorders Metabolic Diseases |